....yeah, sorry guys. Spent a few hours looking at this and just cannot mathematically reverse engineer any convincing unit pricing from OCC's Appendix 4C's. No matter how I vary the lags on cash accounting receipts vs units sales given and base organic sales exclusive of DVT and BH, it just doesn't give a convincingly symmetry with realistic unit prices generated revenues vs cash flows.
This will be easier to do once we get the formal full year accrual accounting results. Its like the accounting dept. went on holiday in 3Q23 and didn't bother collecting cash. One thing is glaring. The cash receipts for the increased sales have not remotely hit yet, unless Striate is being sold for a dollar or pre-existing sales exclusive of BH are of larger numbers (alas we know that's not true):
FY23 Striate units via BH 10936 FY23 Remplir units via DVT 682 FY23 Qtr Sriate Remplir Cash revenues (k) (FY22) 4 5482 362 645 407 3 2339 100 265 313 2 2726 36 500 378 1 389 184 463 356 FY23 10936 682 0 1873 1454
OCC increased its BH Striate sales by 1300% 4Q to 1Q and Remplir by 96% and yet receipts go from only $463K to $645K QoQ? Suspect the forthcoming full year results revenues, that will of course be accounted on an accrual basis, are going to dwarf the reported full year sales receipts that are calculated on a cash flow basis - otherwise something is up with their accounting/reporting.
Even if you went with Jonesing's lowest base gross prices of $45 and $812 for Striate and Remplir, the increase of accrued revenues between the two would be $374K - and $648K at the upper end of the range. Similarly only $645K vs $407K, 4QFY23 vs 4QFY22 after an explosion in relative sales in BH Striate sales across the two. Clearly these unit sales increases have not shown in cash receipts in any remotely consistent fashion in the Appendix 4C's, and a significant portion appear yet reflected at all in accounting figures to date vs reported sales increases.
Me thinks some impressive full year accounts coming our way. An interesting lesson in accrual accounting vs the cash flows - you have to look at both.
- Forums
- ASX - By Stock
- OCC
- Ann: Quarterly Activity Report & Appendix 4C
Ann: Quarterly Activity Report & Appendix 4C, page-30
-
- There are more pages in this discussion • 43 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add OCC (ASX) to my watchlist
(20min delay)
|
|||||
Last
65.5¢ |
Change
-0.030(4.38%) |
Mkt cap ! $156.6M |
Open | High | Low | Value | Volume |
67.0¢ | 67.0¢ | 65.0¢ | $239.3K | 362.1K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 10000 | 65.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
66.0¢ | 4477 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 30123 | 0.650 |
2 | 14260 | 0.645 |
9 | 100853 | 0.640 |
4 | 33664 | 0.635 |
6 | 52386 | 0.630 |
Price($) | Vol. | No. |
---|---|---|
0.660 | 4260 | 1 |
0.665 | 12622 | 2 |
0.670 | 11000 | 1 |
0.675 | 6000 | 1 |
0.680 | 28042 | 3 |
Last trade - 15.58pm 13/11/2024 (20 minute delay) ? |
Featured News
OCC (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online